Small-cell lung cancer (SCLC) represents about 15% of all lung cancers and is marked by
an exceptionally high proliferative rate, strong predilection for early metastasis and poor …

Small cell lung cancer (SCLC) comprises about 15% of all lung cancers. It is an aggressive
disease, with early metastasis and a poor prognosis. Until recently, SCLC treatment …

The tissue distribution and prognostic relevance of subtype‐specific proteins (ASCL1,
NEUROD1, POU2F3, YAP1) present an evolving area of research in small‐cell lung cancer …

Lung cancer is the most malignant human cancer worldwide, also with the highest incidence
rate. However, small-cell lung cancer (SCLC) accounts for 14% of all lung cancer cases …

Lung cancer is the leading cause of cancer mortality in both genders, with non-small cell
lung cancer (NSCLC) accounting for about 85% of all lung cancers. At the time of diagnosis …

Introduction Chemotherapy-induced myelosuppression (CIM) is one of the most common
dose-limiting complications of cancer treatment, and is associated with a range of …

Neuroendocrine neoplasms (NENs) of the lung encompass neuroendocrine tumors (NETs)
composed of typical (TC) and atypical (AC) carcinoids and full-fledged carcinomas (NECs) …

Simple Summary Small cell lung cancer (SCLC) is an aggressive cancer representing 15%
of all lung cancers. Unlike other types of lung cancer, treatments for SCLC have changed …

Background It is well-known that flavonoids, which can be easily obtained from many fruits
and vegetables are widely preferred in the treatment of some important diseases. Some …

Immunotherapy is a major breakthrough in the treatment of cancer in recent years. Immune
checkpoint inhibitors (ICIs) including programmed death-ligand 1 (PD-L1)/programmed …